BL 1021
Alternative Names: BL-1021Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Bar-Ilan-Research-&-Development-Company; Ramot at Tel Aviv University
- Developer BioLineRx
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action Adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Israel (PO)
- 07 May 2012 BL 1021 is available for licensing as of 22 Mar 2012. http://www.biolinerx.com
- 06 Dec 2011 Final adverse events & pharmacokinetics data from a phase I trial in Healthy volunteers released by BioLineRx